Clinical Trial Update: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ATG-019, a dual PAK4 and NAMPT inhibitor, in advanced solid tumors or Non-Hodgkin's lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumor

Drugs mentioned

• ATG-019 (ATG-019)

Snippet

Sponsor: Antengene Therapeutics Limited | Conditions: Solid Tumor, Non-Hodgkin's Lymphoma | Phase 1 | Status: TERMINATED